Cantor Fitzgerald Issues Negative Forecast for ARTV Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Artiva Biotherapeutics in a research report issued on Thursday, November 13th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($3.39) per share for the year, down from their prior forecast of ($3.22). The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. Cantor Fitzgerald also issued estimates for Artiva Biotherapeutics’ FY2026 earnings at ($2.19) EPS.

A number of other equities research analysts have also weighed in on the company. Wedbush boosted their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Finally, HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ:ARTV opened at $3.89 on Monday. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $13.19. The company has a market capitalization of $95.50 million, a PE ratio of -1.51 and a beta of 3.06. The company has a fifty day moving average of $3.40 and a 200-day moving average of $2.71.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth $41,000. Citadel Advisors LLC lifted its holdings in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period. Bank of America Corp DE boosted its position in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $112,000. Finally, BNP Paribas Financial Markets raised its position in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter.

Insider Activity at Artiva Biotherapeutics

In related news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $6.00, for a total value of $153,000.00. Following the sale, the chief executive officer directly owned 356,721 shares in the company, valued at $2,140,326. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 21.40% of the stock is currently owned by corporate insiders.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.